Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Pearl Therapeutics (Redwood City, CA), a clinical-stage pharmaceutical company focused on the development of therapeutics for respiratory diseases, closed a $65M Series D financing. Participants include Vatera Healthcare Partners, 5AM Ventures, Clarus Ventures and New Leaf Ventures. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most […]

Verona Pharma (United Kingdom) a clinical-stage biotechnology company focused on chronic respiratory diseases and inflammation for asthma, COPD, cough, and rhinitis, closed a $11.5M Series A financing. Participants include Henderson Global Investors.

Elevation Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on aerosol therapies for respiratory disease and COPD, closed a $17M Series A financing. Participants include Canaan Partners, Care Capital, TPG Biotech and Mesa Verde Venture Partners.

Funxional Therapeutics (United Kingdom) a clinical-stage small molecule company focused on asthma, COPD and other respiratory disorders, closed a $12.2M Series B financing. Participants include Ventech, Index Ventures and Novo Ventures.

Elevation Pharmaceuticals (San Diego, CA) a preclinical-stage biopharmaceutical company focused on developing improved inhaled drug therapies for COPD , closed a $30M Series A financing. Participants include Canaan Partners, TPG Growth, Care Capital and Mesa Verde Venture Partners.

Acton Pharmaceuticals (Marlborough, MA) a near commercial-stage pharmaceutical company focused on a HFA-propelled aerosol inhaled corticosteroid for the treatment of asthma, closed a $15M Series A financing. Participants include Sequoia Capital.

Altair Therapeutics (San Diego, CA) a clinical-stage biopharmaceutical company focused on antisense therapeutics for asthma and rhinitis, closed a $17M Series B financing. Participants include Domain Associates, AgeChem Venture Fund, Thomas McNerney & Partners and Forward Ventures. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Oxagen (United Kingdom) a clinical-stage biopharmaceutical company focused on asthma and allergic rhinitis based drug company focused on inflammation, closed a $25.M Series C financing. Participants include MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega Ventures, Abingworth, International Bio Trust, Red Abbey Venture Partners and Wellcome Trust. Note: 2009 Year-in-Review Trend Analysis […]

Pulmatrix (Lexington, MA) a clinical-stage biotechnology company focused on the discovery and development of therapies for the treatment and prevention of infectious (COPD, asthma, and cystic fibrosis) and progressive respiratory (influenza, ventilator acquired pneumonia and respiratory syncytial virus (RSV)) diseases, closed a $30.2M Series B financing. Participants include Arch Venture Partners, Novartis Ventures Funds,Polaris Venture […]

Axikin Pharmaceuticals (San Diego, CA) an early-stage company focused on the development of of small-molecule therapeutics for respiratory disorders including allergic rhinitis, asthma and CPOD, closed a $3M Series A financing. Participants include Sanderling Ventures and Mitsui & Co. Venture Partners.

Galleon Pharmaceuticals (Horsham, PA) a discovery-stage company that is focused on building a portfolio of novel medicines for prevalent breathing-control conditions closed a $15M Series A financing. Participants have not been named.

Pearl Therapeutics (Redwood City, CA) development-stage biopharmaceutical company focused on respiratory disorders, closed a $18M Series A financing. Participants include Clarus Ventures, New Leaf Partners, 5AM Ventures and Nektar Therapeutics.

Collegium Pharmaceutical (Cumberland, RI) commercial-stage specialty pharmaceutical company focused on late-stage development therapeutics for central nervous system, respiratory and skin related disorders, closed a $20M Series D financing. Participants include Frazier Healthcare Ventures.

« Previous Entries  Next Page »

to top of page...